Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

Jennifer L. McQuade, Carrie R. Daniel, Kenneth R. Hess, +40

The Lancet Oncology

OncologyBody CompositionCancer ManagementMelanomaMetastatic Melanoma +6

Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

Wolfgang Wick, Vinay K. Puduvalli, Marc C. Chamberlain, +9

Journal of Clinical Oncology

The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts

Jeremy R. Graff, Ann M. McNulty, Kimberly R. Hanna, +16

Cancer Research

Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study

Antoni Ribas, René González, Anna C. Pavlick, +15

The Lancet Oncology

Phase 1BMedicineMelanomaAdvanced Brafv600-mutated MelanomaPathology +5

Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Michael J. Robertson, Brad S. Kahl, Julie M. Vose, +17

Journal of Clinical Oncology

Phase I Dose Escalation and Pharmacokinetic Study of Enzastaurin, an Oral Protein Kinase C Beta Inhibitor, in Patients With Advanced Cancer

Michael A. Carducci, Luna Musib, Merrill S. Kies, +10

Journal of Clinical Oncology

A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors

Cristina Saura, Desamparados Roda, Susana Roselló, +18

Cancer Discovery

A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas

Teri Kreisl, Svetlana Kotliarova, John A. Butman, +5

Neuro-Oncology

Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas

Howard A. Fine, L. Kim, Cheryl Royce, +7

Journal of Clinical Oncology

Angiogenesis InhibitionPathologyHigh-grade GliomasGliomaTumor Biology +15

Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors

Geoffrey I. Shapiro, Patricia LoRusso, Eunice L. Kwak, +15

Investigational New Drugs

Phase Ib StudyMek Inhibitor CobimetinibPi3k Inhibitor PictilisibMedicinePharmacology +4